Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Dothan, Alabama, United States
GSK Investigational Site
Hueytown, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Tuscaloosa, Alabama, United States
GSK Investigational Site
Chandler, Arizona, United States
GSK Investigational Site
Gilbert, Arizona, United States
GSK Investigational Site
Green Valley, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
Start Date
February 1, 2009
Primary Completion Date
January 1, 2012
Completion Date
April 1, 2013
Last Updated
January 9, 2017
1,049
ACTUAL participants
albiglutide
BIOLOGICAL
sitagliptin
DRUG
glimepiride
DRUG
metformin
DRUG
placebo albiglutide
BIOLOGICAL
placebo sitagliptin
DRUG
placebo glimepiride
DRUG
Lead Sponsor
GlaxoSmithKline
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062